CORAL GABLES, FL / ACCESSWIRE / November 26, 2018 / Healthcare stocks remain in focus this week after the stock market posted its worst Black Friday session last week. The Select Sector SPDR Healthcare ETF (XLV) has climbed from lows of $88.98 on Friday to as high as $90.74 this morning. On Monday, the market pushed higher, led by healthcare stocks .
Positive reports from a number of healthcare and biotechnology names this week have helped to propel sector stocks. Heading into the post-holiday week, 4 healthcare stocks to watch include Premier Health Group, Inc. (OTC:PHGRF) (CNSX:PHGI.CN) , CVS Health (NYSE:CVS), Teladoc (NYSE:TDOC), and GW Pharmaceuticals (NASDAQ:GWPH).
Premier Health Group, Inc. (OTC:PHGRF) (CNSX:PHGI.CN) is focused on developing innovative approaches that combine human skill-based expertise with emerging technologies for the healthcare industry. This month, Premier solidified its stance on the increasing opportunity that the legal marijuana industry has presented. This week Premier Health announced an update on its plan to expand the scope of practice within its primary care clinics to include cannabis.
This move could prove to be and exciting one for Premier. The Canadian medical cannabis clinic market is estimated to be worth approximately $2.35 billion by 2025. With this in mind, the company said that it expects to provide additional updates on acquisitions in Q4-18 and Q1-19.
Premier Health Group, Inc. (OTC:PHGRF) (CNSX:PHGI.CN) has engaged discussions with Licensed Producers under the Access to Cannabis for Medical Purposes Regulation, other licensed medical cannabis companies and government officials in order to establish a framework for both patient and physician education. Furthermore, the Company is actively recruiting additional physicians for its existing clinics and a cannabis-focused physician that is licensed in Canada.
Premier Health Group, Inc. (OTC:PHGRF) (CNSX:PHGI.CN) ‘s subsidiary, HealthVue is focused on developing proprietary technology to deliver quality healthcare through the combination of connected primary care clinics with telemedicine and artificial intelligence. The company currently has an ecosystem of over 100,000 active patients and have plans to rapidly increase that number both domestically and internationally.
”With over 110,000 active patients in our clinic ecosystem, it is important that we provide them with the best possible information that allows them to make informed decisions about their personal and family’s health. Providing our family physicians with the appropriate tools and knowledge to prescribe cannabis or with the ability to refer patients to a specialist within our clinics is a key outcome of this initiative,” said Dr. Essam Hamza, CEO of Premier.
CVS Health (NYSE:CVS) saw its shares rally while helping to boost the healthcare sector on Monday. According to reports from CNBC, CVS Health and Aetna have received the final state approval they need to complete their roughly $69 billion merger. CVS and Aetna expect the deal to close “on or about” Nov. 28, the companies said Monday in regulatory filings. The Department of Justice granted preliminary approval in October on the condition that CVS and Aetna removed overlap between their Medicare Part D plans.
On Monday, the New York State Department of Financial Services announced it would approve the deal after CVS and Aetna Health Insurance Co. of New York agreed to a range of consumer protections and said they would spend $40 million on health insurance education measures. Antitrust officials at the Justice Department gave the deal the green light in October, not long after Aetna agreed to sell its Medicare drug business, which overlapped with a CVS unit.
Teladoc (NYSE:TDOC) saw a continued uptrend in its stock on Monday as well. The virtual care company announced today the launch of Best Doctors Specialty Pharmacy Services, the first virtual care solution designed to tackle rising prescription drug costs using advanced analytics and an expert medical opinion. This unique analytics-driven virtual care solution helps employers and plan sponsors identify members with complex conditions such as Crohn’s disease, psoriasis, lupus, or rheumatoid arthritis, and then engages an expert clinical team to carefully review the diagnosis and treatment plan to ensure the right course of action for each patient.
”We already know that Best Doctors services have life-changing results for our plan members – over half that access Best Doctors end up seeing a change in diagnosis or treatment,” said Brad Fedorchuk, Senior Vice-President, Group Customer Experience & Marketing, Great-West Life. ”What makes this program so exciting is that we can now leverage the power of our claims data and data analytics to proactively bring these life-changing services to our members that need them most, and at the same time, help our plan sponsors lower the cost of their benefit programs.”
GW Pharmaceuticals (NASDAQ:GWPH) saw a rally in the market after publishing its latest Phase 3 data. The company reported positive top-line results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of EPIDIOLEX® (cannabidiol or CBD) CV in the treatment of seizures associated with Dravet syndrome, a rare and severe form of childhood-onset epilepsy. In this trial, EPIDIOLEX, when added to the patient’s current treatment, achieved the primary endpoint of reduction in convulsive seizures for both dose levels (10 mg/kg per day and 20 mg/kg per day) with high statistical significance compared to placebo. Both EPIDIOLEX doses also demonstrated statistically significant improvements on all key secondary endpoints.
”The positive results from this trial follow the recent FDA approval, DEA rescheduling and U.S. launch of EPIDIOLEX for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut Syndrome in patients two years and older. These data show an effective dose range in Dravet syndrome that is consistent with our FDA approved label, and which allows for dosing flexibility to address individual patient needs,” stated Justin Gover, GW’s CEO. ”We are proud to have recently launched EPIDIOLEX, the first FDA-approved plant-derived cannabinoid medicine and are excited about its potential to help the lives of patients and their families.”
Shares were up as high as $133.16 during the first half of Monday’s session
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2019 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid ”500,000” shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6) Six month restriction is complete on 4/1/2019 we plan to sell the ”500,000” shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer .